Dechra Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Dechra Pharmaceuticals has been growing earnings at an average annual rate of 14%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 12.5% per year. Dechra Pharmaceuticals's return on equity is 4.8%, and it has net margins of 5.5%.
Key information
14.0%
Earnings growth rate
11.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 12.5% |
| Return on equity | 4.8% |
| Net Margin | 5.5% |
| Next Earnings Update | 04 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Dechra Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 727 | 40 | 280 | 49 |
| 30 Sep 22 | 704 | 49 | 267 | 43 |
| 30 Jun 22 | 682 | 58 | 253 | 36 |
| 31 Mar 22 | 661 | 66 | 239 | 35 |
| 31 Dec 21 | 641 | 73 | 225 | 35 |
| 30 Sep 21 | 624 | 64 | 224 | 36 |
| 30 Jun 21 | 608 | 56 | 222 | 37 |
| 31 Mar 21 | 587 | 50 | 215 | 36 |
| 31 Dec 20 | 566 | 44 | 208 | 35 |
| 30 Sep 20 | 541 | 39 | 203 | 35 |
| 30 Jun 20 | 515 | 34 | 199 | 34 |
| 31 Mar 20 | 507 | 31 | 200 | 34 |
| 31 Dec 19 | 499 | 29 | 201 | 33 |
| 30 Sep 19 | 490 | 30 | 198 | 32 |
| 30 Jun 19 | 482 | 31 | 196 | 32 |
| 31 Mar 19 | 463 | 28 | 191 | 31 |
| 31 Dec 18 | 444 | 25 | 186 | 29 |
| 30 Sep 18 | 426 | 30 | 171 | 28 |
| 30 Jun 18 | 407 | 36 | 156 | 26 |
| 31 Mar 18 | 394 | 40 | 147 | 26 |
| 31 Dec 17 | 381 | 43 | 137 | 26 |
| 30 Sep 17 | 370 | 35 | 133 | 26 |
| 30 Jun 17 | 359 | 26 | 129 | 26 |
| 31 Mar 17 | 334 | 19 | 122 | 23 |
| 31 Dec 16 | 309 | 11 | 115 | 19 |
| 30 Sep 16 | 278 | 12 | 105 | 15 |
| 30 Jun 16 | 248 | 13 | 95 | 10 |
Quality Earnings: DPH N has high quality earnings.
Growing Profit Margin: DPH N's current net profit margins (5.5%) are lower than last year (11.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DPH N's earnings have grown by 14% per year over the past 5 years.
Accelerating Growth: DPH N's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DPH N had negative earnings growth (-45%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (8.1%).
Return on Equity
High ROE: DPH N's Return on Equity (4.8%) is considered low.